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1. Introduction 
Anatomic breast imaging techniques such as mammography and ultrasound are very useful 
in the detection of breast cancer, but can have limited sensitivity and positive predictive 
value, particularly in patients with dense breasts (Kolb et al., 2002). These limitations have 
provided the impetus for adjunctive technologies such as nuclear medicine and PET based 
diagnostic imaging procedures. The nuclear medicine based technique is referred to as 
Breast-Specific Gamma Imaging (BSGI) or molecular breast imaging (MBI) while the 
positron-emission tomography (PET) based technique is referred to as Positron Emission 
Mammography (PEM). Both have demonstrated good results in clinical studies and are 
increasingly being adopted into clinical practice. Although these imaging techniques have 
similarities, they are different in several aspects. This chapter is designed to provide an 
overview of these imaging technologies and their potential roles in patient management. 
2. Radiotracers 
Both BSGI/MBI and PEM are physiologic imaging modalities conducted through the 
injection of a pharmaceutical, called a tracer, which is tagged with a radioactive isotope and 
the resulting molecule is called a radiotracer. Each radiotracer is designed to bind to a 
specific target (organ, tissue, physiologic process, cell receptor or protein) while the isotope 
tag emits radiation that is detected by cameras placed near the patient. The cameras provide 
an image of the distribution of the radiotracer tracer and thus measure a specific physiologic 
process in the area being imaged.  
2.1 Isotopes 
There are two types of radioactive isotope tags used in medical imaging: single gamma 
emission isotopes and positron emission isotopes. Single gamma emission isotopes release a 
gamma ray from the nucleus.  There are a variety of single gamma isotopes used in nuclear 
medicine. The most common isotopes used in diagnostic imaging are referred to as low-
energy isotopes with gamma-ray energies ranging from 80 – 200 kiloelectron volts (keV). 
The gamma ray is a photon with sufficient energy to exit the body and be captured by 
specially designed detectors called gamma cameras. Positron emission isotopes emit a 
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positron, an antimatter particle with the same mass as an electron, but with a positive 
charge. This positron travels a short distance from the nucleus prior to colliding with an 
electron. Since the positron is a particle traveling through the tissue until this collision, the 
patient radiation dose associated with positron emission isotope studies is generally higher 
than that from single gamma emission isotope examinations. This collision results in 
annihilation of both particles converting the mass of the two particles into energy and  
producing a pair of 511 kiloelectron volt (keV) gamma rays traveling approximately 180 
from each other. In positron emission tomography imaging (PET) these gamma rays exit the 
body and are captured by a pair of opposed gamma cameras.    
The units for measuring the activity of radiotracer delivered to the patient are the Becquerel 
and the Curie. The Becquerel (symbol Bq) is the SI-derived unit of radioactivity. One Bq is 
defined as: one decay (emission) per second. The curie (symbol Ci) is a unit of radioactivity, 
defined as 3.7×1010 decays per second. In breast imaging, the megabecquerel (MBq) and 
millicurie (mCi) are the most common units used; one millicurie equals 37 Megabecquerel. 
These units only describe the number of decays per second for a given sample and are not to 
be confused with the units used to describe the radiation dose they deliver to a patient. A 
more detailed discussion of radiation dose is provided in Section 4.   
2.1.1 Pharmaceuticals for BSGI/MBI  
BSGI/MBI is a single photon imaging technique that has been conducted using a variety of 
imaging agents, but the most common is 99mTc-hexakis-2-methoxyisobutylisonitrile also 
referred to as 99mTc-Sestamibi or MIBI. MIBI is a 140 KeV gamma ray emitting isotope in a 
lipophilic cation molecule. It was originally cleared by the US FDA for use as a cardiac 
perfusion agent; breast imaging was subsequently added subsequently breast imaging was 
added as an indication following additional clinical studies to determine its efficacy in this 
application. It is injected intravenously and is retained in cells likely by electronegative 
cellular and mitochondrial membrane potentials (Piwnica-Worms et al., 1990). Studies show 
that its accumulation is roughly proportional to blood flow, desmoplastic activity and 
cellular proliferation and therefore it accumulates preferentially in breast cancers compared 
with surrounding tissues (Cutrone et al., 1998). It is a lipophilic substrate for the P-
glycoprotein (Pgp), a cellular efflux pump for various compounds (Ballinger et al., 1995). 
Therefore, Sestamibi exhibits rapid tumor wash-in (within about 2 minutes) followed by a 
slow tumor washout (over the course of several hours) (Sciuto et al., 2002). Based on these 
factors, imaging can begin within minutes after injection and can continue for up to about 90 
minutes post injection, providing ample time for all required views to be conducted before 
the washout cycle negatively impacts lesion-to-background tracer concentration ratio. In 
addition, since the level of Pgp expression correlates with tumor response to cytotoxic 
chemotherapy, a comparison of immediate and delayed images (4 hours post injection) may 
be used to quantify the radiotracer washout as a measure of Pgp expression and the 
probability of multi-drug resistance.  
There are no known contraindications for use. Reactions to Sestamibi are generally minor 
according to the Cardiolite drug data sheet. In the analysis of potential reactions, 3068 
patients (77% men, 22% women, and 0.7% not recorded) were documented from the cardiac 
clinical trials and 673 were recorded from the breast imaging trials. Of the 673 breast 
imaging patients, all of whom were women, the most common reported reaction was taste 
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perversion with most of those patients reporting a metallic taste at the time of injection. The 
other minor reactions are listed in table 1. More serious reactions were reported in less than 
0.5% of patients and included: signs and symptoms consistent with seizure occurring 
shortly after administration of the agent; transient arthritis, angioedema, arrythmia, 
dizziness, syncope, abdominal pain, vomiting, and severe hypersensitivity characterized by 
dyspnea, hypotension, bradycardia, asthenia, and vomiting within two hours after a second 
injection of Technetium Tc99m Sestamibi. However the list of serious reactions is from the 
total population of patients including men and women undergoing a cardiac stress test.   
 
Body System N = 673 
Body as a whole 21 (3.1%) 
Headache 11 (1.6%) 
Cardiovascular 9 (1.3%) 
Angina 0 (0%) 
ST segment changes 0 (0%) 
Digestive System 8 (1.2) 
Nausea 4 (0.6%) 
Special Senses 132 (19.6%) 
Taste Perversion 129 (19.2%) 
Parosmia 8 (1.2%) 
Table 1. Reactions to Sestamibi from 673 breast imaging patients. 
2.1.2 Pharmaceuticals for PEM 
PEM is a positron emission imaging technique conducted with 2-[fluorine-18] fluoro-2-
deoxy-D-glucose (FDG), a modified glucose molecule with a positron-emitting isotope. 
Breast cancers exhibit a greater uptake of FDG than the surrounding breast tissue due to 
their hyperglycolytic rate. For some malignant lesions, although they possess an elevated 
GLUT-1 transmembrane transport function, however this does not necessarily result in 
increased tracer uptake (Smith, 1999). Studies have established that the uptake of FDG is 
primarily dependent on blood flow, the type of breast malignancy and the microstructure of 
the lesion (nodular vs. diffuse) (Avril et al., 2001). For example, lobular carcinoma exhibits a 
roughly 30% lower uptake than ductal carcinoma (Avril et al., 2001). For the PEM 
procedure, patients must fast 4 – 6 hours prior to the injection of FDG. It is important to note 
that patients with compromised glucose metabolism should have their glucose level 
checked prior to the administration of FDG and at least one study reports that altered 
glucose metabolism can affect the sensitivity of this procedure (Berg et al., 2006). FDG is 
administered intravenously and imaging is conducted approximately 60-90 minutes post 
injection in order to allow sufficient time for glucose uptake into the tissue. Patients should 
be requested to sit quietly in a dark, calm room to avoid manipulating the distribution of 
FDG. A dual-phase imaging technique may be used to improve specificity of the study 
(imaging at both 60 and 90 minutes post injection).  
The emitted positron has a mean free path of approximately 1 mm in the breast tissue before 
annihilation with an electron resulting in the emission of two 511 KeV gamma rays. The 
random nature of the displacement between the positron and gamma ray points of origin 
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has some impact on the lower limit of spatial resolution in studies using positron-emitting 
isotopes (Turkington, 2001). 
2.2 Comparison of BSGI/MBI and PEM Radiotracers 
Both Sestamibi and FDG demonstrate increased accumulation in breast cancers, although 
the mechanism for this accumulation is better understood for FDG. In addition, although the 
breast tissue typically has a homogeneous uptake of both tracers, they can accumulate in 
normal glandular tissue resulting in a diffuse heterogeneous uptake pattern, especially in 
pre-menopausal women who are in the luteal phase of their menstrual cycle (Lin et al., 
2007). This is not surprising as it reflects the heterogeneous nature of the breast tissue and 
the impact of blood hormone levels on the breast parenchyma. This heterogeneity does not 
generally impact cancer detection, but may complicate interpretation. The intensity of this 
pattern can be reduced for both tracers by imaging outside of the luteal phase and several 
studies report that day 2 – 14 of the menstrual cycle is optimal. Neither tracer is linked to 
nephrogenic systemic fibrosis, a sometimes fatal condition that is associated with 
gadolinium contrast agents used in breast MRI. MIBI has some minor pharmacologic 
considerations and rare reactions occurring in less than 0.5%of patients.  FDG imaging 
requires fasting for a minimum of 4 hours prior to injection and as mentioned in the 
previous section, it is beneficial to check the blood glucose level prior to FDG administration 
as the tumor uptake of FDG is reduced in hyperglycemic states (Schelbert et al., 1999) and 
this results in some potential for complications and reduced sensitivity for the procedure in 
diabetic patients. In comparison, MIBI does not require fasting and imaging can be 
conducted within minutes of the injection.   
Some of the physical and clinical differences between FDG and MIBI imaging are 
summarized in Tables 2 and 3 respectively.  
 
 
Energy of 
Emission photon 
Half Life 
(minutes) 
FDG 511 KeV 110 
MIBI 140 KeV 360 
Table 2. gamma-ray emission information for radiotracers. 
 
 Pre-study Fasting 
Injection to 
Imaging time 
Recommended 
Pre-procedural testing 
FDG 4 - 6 hours 
60 – 90 
minutes 
Blood glucose 
MIBI None 5 minutes None 
Table 3. Radiotracer administration and imaging considerations. 
3. Imaging systems 
Both the single gamma and positron isotopes described in section 2.1 ultimately emit 
gamma rays (the positron isotopes through the annihilation and the conversion of the 
positron) that exit the patient’s body and can be detected with external detectors. The goal of 
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these detector systems is to reconstruct the gamma ray emissions into an image that allows 
the physician to visualize the distribution of the radiotracer in the body. There are two 
modes of image reconstruction, plannar and tomographic. The planar method results in a 
single 2-dimensional image per acquisition, similar to the mammogram. Tomographic 
reconstruction provides a 3-dimensional reconstruction of the breast similar to MRI. The 
single gamma detector systems used for BSGI/MBI can be planar or tomographic and can 
be constructed of a single or multiple detectors. The positron imaging systems used for PEM 
by their design provide tomographic imaging only and since the detection of the pair of 
gamma rays is required for image reconstruction, positron systems must consist of either a 
pair of opposed detectors or a ring detector design.  
3.1 Gamma-ray imaging basics 
The detection of an abnormality in BSGI and PEM imaging is based on the ability of the 
imaging system to depict the variations of uptake in the tissue. Unlike anatomical imaging 
where high spatial resolution is needed to visualize the detailed morphology used to 
provide differential diagnosis, the molecular imaging system must provide sufficient image 
contrast in order to visualize the variations in radiotracer uptake; the contrast between 
radiotracer concentration in the tumor and the uptake of the surrounding breast tissue. 
While this is partially a function of resolution, there are several other factors impacting 
imaging. This contrast based imaging requires a careful balance between spatial resolution, 
image noise and photon sensitivity. Generally, as spatial resolution increases, image noise 
increases and photon sensitivity decreases proportionally to some degree thus if spatial 
resolution is increased to a level where the detector has poor photon sensitivity and the 
resulting image noise is too high, the ability of the system to visualize the contrasting tissue 
uptake is diminished. A detailed discussion of the balance between these factors is beyond 
the scope of this text, but it is important to realize that in molecular imaging is a contrast 
based imaging and spatial resolution is not the only parameter affecting the visualization of 
lesions. For example, it is possible to detect a 1 mm cancer using a system with a 4 mm 
spatial resolution if the uptake of that lesion is sufficiently enough higher than the 
background to overcome the partial volume effect. Conversely, a 40 mm cancer could be 
missed by the same imaging system if the lesion uptake is not sufficiently higher than the 
surrounding tissue. 
As an illustration, nearly all commercially available large field-of-view gamma cameras, 
typical to the nuclear medicine department, have a variable matrix setting, including 512 x 
512, 256 x 256 and 128 x 128. Although the 512 x 512 setting produces the highest spatial 
resolution, nearly all nuclear medicine studies are conducted on the 256 x 256 or 128 x 128 
settings because the resulting image noise at the 512 x 512 setting diminishes image quality 
for the majority of studies. 
System photon sensitivity is another important parameter in BSGI/MBI and PEM imaging. 
As photon sensitivity increases, the amount of radiotracer, the length of time the image is 
acquired, or some combination of both parameters can be decreased. For Example: a given 
detector system is providing good clinical images using a dose of 300 MBq and an 
acquisition time of 10 minutes. If the photon sensitivity of this system can be increased 50% 
the clinician would have three possible options. First, they could reduce the patient’s 
radiation exposure by reducing the amount of radiotracer delivered to the patient by 50%, to 
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150 MBq and maintain the same imaging time, 10 minutes. Second, they could reduce the 
imaging time by 50% to 5 minutes using a 300 MBq dose. Or third, they could reduce both 
the time and the dose by roughly 25% resulting in a dose of 225 MBq and an imaging time of 
7.5 minutes. It is important to remember that in molecular imaging techniques such as 
BSGI/MBI and PEM, the imaging time and the dose delivered can be manipulated, but 
reducing both to any large degree is not possible unless significant improvements in photon 
sensitivity are obtained.   
3.1.1 BSGI/MBI Imaging 
BSGI/MBI imaging is conducted with a single-head or dual-head detector system (see 
Figure 1). Only one detector equipped with a collimator is required for image 
reconstruction. Generally, gentle breast compression (normally less than 12 lbs or 53 
newtons) is used to provide breast immobilization. This compression is noticeably lower 
than that used in mammography for two reasons. First, the typical imaging time for a single 
BSGI/MBI image is significantly longer than that needed for a mammographic projection, 5 
– 10 minutes, thus lower pressures are better tolerated by patients and second, the 140keV 
gamma ray emitted in BSGI/MBI has sufficiently higher tissue penetration than the 8 – 35 
keV x-ray used in mammography therefore these images benefit less from higher 
compression. As shown in figure 1, in the single-head design a paddle is used to provide 
compression and in the dual-head system, the breast is compressed between the detectors. 
The compression paddle used in the single head system can be exchanged for a fenestrated 
paddle to allow biopsy. Biopsy is currently not available on the dual-head design. 
  
Fig. 1. A single and dual head imaging system for BSGI/MBI. 
3.1.2 BSGI/MBI detectors 
As mentioned in the previous section, there is generally an inverse relationship between 
photon sensitivity and spatial resolution however both are important to imaging. These 
parameters are determined by several aspects of the detector design, especially that of the 
collimator. The most commercially available systems have an extrinsic spatial resolution of 
between 1.9 and 3.3 mm at the surface of the detector however it is important to note that 
the spatial resolution of planar, single gamma imaging systems decreases with increasing 
source-to-collimator distance, thus the spatial resolution of a lesion near the detector is 
better than that of one deep in the breast tissue, relative to the detector face. For example, if 
the breast is being imaged in the cranio-caudal position (detector inferior to the breast 
tissue), lesions in the inferior portion of the breast tissue will be somewhat more visible than 
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those in the superior portion of the breast. This resolution loss is, at least in part, the driving 
logic behind the dual-head opposed detector design. In theory, if the breast is imaged using 
a dual-head system in the cranio-caudal position, the upper detector would maximize 
visualization of the superior portion of the breast while the lower detector optimizes 
visualization of inferior lesions.  
Although there is a theoretical benefit to the dual-head design, it is interesting to note that 
clinical data from the dual-head and single-head systems shows similar performance in 
terms of lesion sensitivity (see section 5 below). This is likely due to the two-view imaging 
protocol adopted from mammography that is standard in BSGI/MBI protocols.  Just as in 
mammography, the optimal coverage of breast tissue is obtained by acquiring an MLO and 
CC image of each breast and additional images are obtained as needed. Since all patients 
have a minimum of two views obtained, the likelihood of a lesion being deep to both 
projections is quite small. In addition, similar to mammography, when a lesion is seen in 
only one image, additional images are obtained in order to determine the location of the 
lesion in the breast tissue. As long as this two-view protocol remains the standard, it is 
unlikely that the dual-head system will result in significant improvements in the sensitivity 
of the detection of breast malignancies. However, provided the two detector images are 
fused properly, it may be possible to reduce either the injected dose or the acquisition time 
to facilitate low-dose imaging or higher throughput on the imaging system.  
Single photon emission computed tomography (SPECT) is a recent development in 
BSGI/MBI. Currently these devices are only available in the research setting (Williams et al., 
2010). Additional research is needed to determine if dual-head image combination 
techniques or the implementation of SPECT imaging will provide a clear benefit to 
BSGI/MBI in terms of breast cancer detection. Such studies are underway, but the data is 
not yet available for analysis.     
   
Fig. 2. Left and Center - a single-head BSGI/MBI system with a compression paddle used 
for positioning. The left image illustrates the cranio-caudal (CC) position and the center 
image illustrates the medial lateral oblique position (MLO). The right image illustrates the 
MLO position with the dual-head system where the compression paddle is replaced by a 
second detector. 
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Fig. 3. A typical 4-view BSGI study. 
3.1.3 Detectors for PEM  
PEM imaging is conducted with either a dual head or ring style gamma-ray detector. Both 
systems are designed to detect the coincident gamma rays which, are traveling 
approximately 180° from each other after the annihilation reaction (see figure 4). Unlike 
BSGI imaging devices, PEM devices do not use a collimator to help determine the location of 
each event. In PEM imaging, since there are two gamma-rays traveling 180° apart, the event 
location is calculated as a line of response between the location that each gamma-ray strikes 
the pair of opposed detectors. One advantage to PEM is that it does not have the same loss 
of resolution with distance that BSGI/MBI systems experience. As mentioned in the 
previous section, the mean free path of the 18F positron within the breast tissue is 
approximately 1 mm and commercially available PEM systems report an in-plane spatial 
resolution of about 2 mm. One limitation of the dual-head PEM detector design is that, due 
to the limited angle of acquisition, it has limited resolution in the Z-axis (depth).  Ring 
detectors do not suffer from this limitation as they provide a 360° acquisition for 
reconstruction however there is currently no biopsy capability on the ring detector systems. 
A needle biopsy localization device was recently introduced for the opposed dual-head 
detector system. 
    
Fig. 4. The left image provides an example of an opposed dual-head imaging system while 
the system on the right is an example of a ring detector system. 
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One limitation to PEM image reconstruction is that the detector photon sensitivity is not 
linear across the field-of-view with lower sensitivity along the detector edges. This causes a 
higher level of noise to be present in the breast images, along the chest wall. Figure 5 
provides a schematic representation of factors affecting the photon sensitivity in a PEM 
detector. The maximum angle of reconstruction (MAR) is a setting used in PEM software 
and it is defined as the maximum angle away from the detector normals (90 from the 
detector face) for which coincident gamma ray detections are included in tomographic 
image reconstruction. Larger MAR values yield greater overall photon sensitivity but with 
potential loss in spatial resolution due to the depth-of-interaction (DOI) blur. The blue lines 
in Figure 1 show the angular range over which gamma rays emitted from two points in the 
breast are accepted. Figure 1A shows a point near the nipple, and Figure 1B shows one near 
the chest. For events that occur in the center of the field-of-view (FOV), all of the events 
within the MAR are captured by the detector system. However a significant fraction of 
events occurring near the FOV edges go uncounted for because one of the paired gamma 
rays traveling outside the edges of the detector is not detected. As a recent study found, this 
loss of photon sensitivity along the edges limits the ability of the PEM system to detect 
lesions located near the chest wall (Rosen et al, 2005).  
 
Fig. 5. A and B: a schematic example of the maximum angle of reconstruction near the center 
of the detector field-of-view and then near the chest wall respectively. 
    
Fig. 6. a typical PEM study with multiple slice reconstruction for each projection. 
Detector 1 Detector 1
Detector 2Detector 2
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PEM detectors are tomographic imaging devices, an example image from the opposed 
detector system is provided in Figure 6. Note the noise level along the chest wall and the  
Z-resolution affect is expressed as a blurry, low intensity focus in the reconstruction planes 
outside of the plane the lesion is located in. In this particular case, it is most noticeable in the 
MLO projection images. There is noticeable residual blur in the area of the largest lesion in 
all of the projections, including those outside of the lesion. 
4. Radiation dose 
As with all nuclear medicine procedures, the detector systems do not emit radiation. The 
radiation dose delivered to the patient in these procedures comes from the radiotracer and is 
dependent on both the activity of the radiotracer injected and the biologic distribution of the 
tracer in the organs. 
4.1 BSGI/MBI radiation dose 
Sestamibi (MIBI) was cleared by the US FDA in 1991 for cardiac perfusion studies. In 1997, 
breast imaging was added as an indication to the drug package insert following a clinical 
trial conducted with standard gamma cameras equipped with high-resolution collimators. 
According to the drug package insert, the patient whole-body radiation dose is 4.8 milligray 
at 1110 megabecquerels (0.5  rads at 30 millicuries), see Table 4. According to the Dosage 
and Administration section of the drug package insert, breast imaging is to be conducted 
using a dose of 740 – 1110 MBq (20 – 30 mCi).  
At the time of the US FDA approval, the breast imaging studies were being acquired with 
standard, large field-of-view gamma cameras, typical to a nuclear medicine department and 
the dose required for imaging was determined largely by the low photon sensitivity of these 
imaging systems when equipped with high-resolution collimators (Khalkhali et al., 2004) 
Since that time, several breast optimized gamma camera systems have been developed with 
significantly higher photon sensitivity and several studies indicate that it is possible to lower 
the injected dose of MIBI required for breast imaging with these systems.  
A recent clinical trial was conducted to examine breast tissue uptake as a function of 
injected dose. The results of this analysis indicate that breast tissue uptake of MIBI 
appears to be linear relative to the injected dose thus implying there is no physiologic 
limitation to using lower doses (Böhm-Vélez et al., 2011). According to additional studies, 
conducted by the Mayo Clinic, the new, breast optimized detector systems provide a 
photon sensitivity roughly 3 times higher than that of the older imaging systems (Hruska 
et al., 2008). 
From the available data, it is evident that these new detector technologies can reduce the 
dose required to conduct breast imaging with MIBI. Reducing the dose MIBI from 740 – 
1110 MBq (20 – 30 mCI) to 259 – 370 MBq (7 – 10 mCi) reduces patient radiation exposure by 
nearly a factor of 3. The radiation exposure from a 259 MBq injection of MIBI is 
approximately 2 millisieverts (mSv) and is approximately equivalent to the radiation dose 
diagnostic breast patients receive from the combination of screening and diagnostic 
mammograms (Hendrick, 2010; Valinten, 2007).  
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Table 4. Radiation dosimetry of Sestamibi. 
 
Graph 1. The relative photon sensitivity of commercially available, breast-optimized 
imaging systems compared to that of the standard gamma camera. 
4.2 PEM radiation dose 
F-18 fluorodeoxy-D-glucose (FDG) was cleared by the US FDA in 2000 for a variety of uses 
including tumor localization. The total body radiation dose in FDG PET is 39 mrads per mCi 
injected activity (Table 5). According to the clinical literature, the typical FDG dose used for 
imaging with the standard whole body PET detectors ranges between is approximately 370 - 
740 MBq (10 - 20 mCi). 
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Table 5. Radiation dose for FDG based on 1 mCi injection. 
The dose of FDG used for PEM studies has generally followed the guidelines established 
with the lager systems, typically using approximately 444 MBq (12 mCi) (Berg et al, 2006). 
However, more recent studies have demonstrated that doses of 111 – 185 MBq (3 – 5 mCi) 
are possible with the breast-optimized imaging systems (MacDonald et al, 2010). The 
resulting radiation dose to the patient is 1.9 – 3.1 mSv using a low dose protocol, nearly 
identical to that of low dose BSGI/MBI (O’Connor et al., 2010).   
5. Clinical evidence 
There is a substantial history of clinical literature on imaging breast cancers with nuclear 
medicine techniques. One of the first reports of breast imaging using MIBI was provided by 
Campeau and his colleagues in 1992 while the first report of breast cancer imaging using 
FDG was reported by Wahl the previous year (Campeau et al., 1992; Wahl et al,. 1991) Since 
that time, hundreds of articles have been published on breast imaging using these 
radiotracers. However until recently, these imaging studies were conducted with large 
gamma cameras typical in the nuclear medicine department. The development of breast-
optimized detector systems used in BSGI/MBI and PEM is more recent and the primary 
advantage of these systems is that they provide higher sensitivity for the detection of breast 
lesions than their predecessors.  
5.1 Clinical evidence for BSGI/MBI  
There have been several clinical studies evaluating BSGI/MBI in breast cancer detection. In 
2008, the group from George Washington Medical University provided an overview of their 
experience using BSGI/MBI in 146 patients who participated in an IRB approved trial (Brem 
et al., 2008). Table 6 provides the reported sensitivity of BSGI for various subgroups from 
that analysis.  
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Overall 96% 
Invasive Cancers 97% 
Sub-centimeter lesions 89% 
Lobular Carcinoma 93% 
DCIS 94% 
Table 6. The sensitivity of BSGI in various subgroups. 
Other, larger studies have provided evidence of high sensitivity and specificity for BSGI. 
The first of these larger studies was an analysis performed by Weigert and her associates in 
more than 500 women who had a BSGI scan performed as part of their routine diagnostic 
imaging following conventional imaging (Weigert et al., 2007). It is interesting to note that 
over half of the patients in this study had indeterminate findings following mammography 
and ultrasound. Two years later, Bertrand presented the results from a retrospective, 
multicenter study reporting that BSGI provided a higher sensitivity than diagnostic 
mammography in detection of breast cancer, especially in the high-risk and dense breast 
populations (Bertrand et al., 2009) Last, in 2011, Lee et al reported that BSGI had a higher 
sensitivity than mammography and higher specificity than ultrasound in their series of 622 
patients who had all three imaging modalities performed as part of their diagnostic 
examination (Lee et al., 2011).  In addition, this work found that there was no change in the 
sensitivity of BSGI between normally dense and heterogeneously or very dense breast 
tissue. 
 
 Bertrand, 2009 Lee, 2011 Weigert, 2007
Total Patients 1,042 662 512 
Sensitivity (%) 91 95 89 
Specificity (%) 77 88 90 
NPV (%) 96 97 98 
Table 7. The clinical performance of BSGI from several studies. 
5.2 Clinical evidence for PEM 
One of the earliest published studies on PEM containing a group of 77 patients examined 
the effectiveness of PEM in the detection of breast carcinoma (Berg et al., 2006). Table 8 
provides the sensitivity of PEM as determined by this work.  As expected, the sensitivity for 
lobular carcinoma was somewhat lower potentially due to the reduced glucose metabolism 
compared to ductal carcinoma. 
 Sensitivity 
Overall 90% 
DCIS 91% 
ILC 75% 
Sub-centimeter 63% 
Table 8. Sensitivity of PEM by sub-group. 
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The overall sensitivity and specificity for PEM is very good, especially for DCIS. Table 9 lists 
for each of the four PEM studies cited, the total number enrolled, the sensitivity, specificity, 
and negative predictive value. 
 
 Berg, 2006 Tafra, 2005 Schilling, 2011
Total Patients 77 44 182 
Sensitivity (%) 90 89 85 
Specificity (%) 86 NR 74 
NPV (%) 88 NR NR 
Table 9. Clinical results of PEM imaging. NR = not reported. 
In clinical studies of BSGI/MBI and PEM, both of these metabolic imaging modalities 
provide improved sensitivity and specificity for the diagnosis of breast cancer compared to 
mammography alone. The sensitivity and specificity of BSGI and PEM are generally 
comparable with both modalities demonstrating the capability to visualize lesions as small 
as 1 – 2 mm. Both PEM and BSGI/MBI systems have biopsy guidance capabilities. 
6. Clinical considerations 
Both BSGI and PEM provide valuable clinical information in the detection and treatment of 
breast carcinoma. Like all imaging studies, each has distinct advantages and limitations. From 
the clinical data, it is evident that the performance of these modalities is quite comparable.  
The biggest differences between the procedures are logistical. First, in most areas, MIBI is 
more readily available and significantly less expensive than FDG. In addition, the shorter 
half-life of FDG puts tighter constraints on the clinical schedule. For example, if a patient 
arrives 1 hour late for a FDG injection, the dose has lost 32% of the intended activity where 
as a MIBI dose has lost 9%. Also, the use of FDG requires four hours of patient fasting prior 
to injection and MIBI does not have this constraint. FDG also requires a 1-hour post-injection 
delay for imaging where as MIBI imaging can begin immediately post injection. Based on 
the injection-to-imaging time considerations, total time required for a MIBI study is 
approximately 45 minutes compared to approximately 2 hours for an FDG study. 
7. Clinical indications 
Several indications for these technologies have been proposed in the medical literature. 
Generally speaking, BSGI/MBI has been examined as a diagnostic adjunct to 
mammography and ultrasound when these imaging modalities are inconclusive or 
discordant with other imaging studies and/or clinical signs and symptoms and there is a 
remaining diagnostic concern.  In addition, there is good data to suggest that it is also useful 
in pre-operative treatment planning for patients with known malignancy and in monitoring 
the response of the breast lesion(s) to neoadjuvant chemotherapy, see section 5.1. The 
majority of studies on PEM have examined its use as in preoperative treatment planning for 
patients with know malignancy and in monitoring the response of breast tumor(s) to 
neoadjuvant chemotherapy.  
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In June of 2009, an interdisciplinary committee established by the American College of 
Surgeons published a report to provide guidance on the use of imaging techniques in breast 
patients (Silverstein et al., 2009). This panel grouped BSGI/MBI and PEM together as 
molecular  imaging techniques and issued the following recommendation: 
- “The available information suggests that they (BSGI/MBI and PEM) may have 
equivalent sensitivity and improved specificity when compared with breast MRI. It is 
recommended that these adjunctive tools be used only after high-quality standard 
imaging is performed; their results should not prevent performing a biopsy 
recommended after conventional imaging. Either breast-specific gamma imaging or 
positron emission mammography may be used as an alternative to breast MRI when 
MRI is not available or is contraindicated in a particular patient. Both tools may be 
valuable in pre-operative surgical staging. Breast-specific gamma imaging may also be 
useful as an additional problem-solving tool in some situations.” 
7.1 Recognized BSGI/MBI indications 
In June 2009, the Society of Nuclear Medicine released the Procedural Guidelines for Breast 
Scintigraphy with Breast-Specific Gamma Cameras that included several proposed several 
indications for BSGI/MBI (Goldsmith et al., 2009). The indications are quite specific and 
echoed those set forth by the American College of Surgeons. The indications can be grouped 
into 4 primary categories.  
1. As a diagnostic adjunct for patients with indeterminate findings on conventional 
imaging (mammography, ultrasound and/or MRI) and remaining diagnostic concerns 
such as palpable mass, nipple discharge, pain, etc. 
2. Preoperative treatment planning in patients with a known cancer diagnosis to 
determine the extent of the primary lesion and to detect additional foci of disease. 
3. As an alterative to breast MRI for patients whom MRI is indicated, but not possible; 
ferromagnetic implants, compromised renal function, etc. 
4. Monitoring tumor response to chemotherapy.  
7.2 Recognized PEM indications 
There are no additional published guidelines for PEM other than those of the American 
College of Surgeons that essentially provided three indications: 
1. Pre-operative treatment planning in patients with a known cancer diagnosis to 
determine extent of the primary lesion and to detect additional foci of disease. 
2. To monitor the response of breast tumor(s) to neoadjuvant chemotherapy. 
3. As an alternative to breast MRI in patients for whom MRI is indicated, but not possible; 
ferromagnetic implants, compromised renal function, etc. 
8. Conclusion 
BSGI/MBI and PEM are adjunctive molecular breast imaging technologies which are 
becoming more common in the breast center and they provide very similar performance in 
terms of sensitivity and specificity. The radiation dose associated with these imaging 
techniques is similar to that patients receive from other diagnostic imaging procedures such 
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as CT, PET and nuclear medicine thus their use is currently limited to the diagnostic patient 
population. However, several studies are underway to reduce the radiation dose to the level 
of screening mammography which will likely increase their utility to breast cancer screening 
in the asymptomatic population. The BSGI/MBI procedure is a useful problem-solving tool 
for patients with dense or complex breast tissue and an unresolved diagnostic concern 
following anatomical imaging procedures such as mammography and ultrasound. Both 
BSGI/MBI and PEM are useful in breast cancer patients to detect the extent of disease 
(additional occult multifocal or muticentric disease) and to monitor tumor response to 
neoadjuvant chemotherapy. PEM has the advantage of tomographic reconstruction and 
uniform spatial resolution with increasing tumor depth. In addition, for the breast cancer 
patient undergoing a PET/CT scan for staging, it is possible to conduct the PEM study 
following the PET/CT without an additional administration of FDG. The advantages for 
BSGI/MBI are superior photon sensitivity along the chest wall, fewer patient restrictions 
and the wider availability of MIBI (see the considerations section above). 
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